Heidelberg Pharma AG Shareholders Approve All Agenda Items at Annual General Meeting; Jack Yefei Ling Elected to Supervisory Board

Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company specializing in innovative Antibody Drug Conjugates (ADCs), announced that its shareholders approved all management proposals with a large majority (between 98.67% and 98.72%) at the ordinary virtual Annual General Meeting held on June 23, 2026. The high approval rates reflect strong shareholder support for the company's governance and strategic decisions.

Key resolutions included the formal approval of the actions of the Management Board and Supervisory Board for the 2024/2025 financial year, the appointment of auditors for the 2025/2026 financial year, and the approval of the remuneration report for the Management Board. Additionally, shareholders elected Mr. Jack Yefei Ling as a new member of the Supervisory Board. The meeting also approved an amendment to the Articles of Association to reduce the size of the Supervisory Board from seven to five members.

The attendance, including postal votes, represented 80.55% of the current capital stock, indicating robust shareholder engagement. Detailed voting results and further information are available on the company's website at https://heidelberg-pharma.com/en/agm.

Heidelberg Pharma is pioneering cancer therapies using Amanitin, a toxin derived from the death cap mushroom, through its proprietary ATAC (Amanitin-based ADC) technology. The lead candidate, HDP-101 (INN: pamlectabart tismanitin), targets BCMA and is in clinical development for multiple myeloma, having received Orphan Drug Designation and Fast Track Designation from the FDA. Other programs include HDP-102 for Non-Hodgkin Lymphoma, HDP-103 for metastatic castration-resistant prostate cancer, and HDP-104 for gastrointestinal tumors such as colorectal cancer, which are available for partnering.

The strong shareholder approval at the Annual General Meeting underscores confidence in Heidelberg Pharma's strategic focus on its ATAC technology and its pipeline of ADC candidates. The election of Jack Yefei Ling to the Supervisory Board brings additional expertise as the company advances its clinical programs and explores partnership opportunities.